Navamedic Valuation

Is NAVA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NAVA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NAVA (NOK25.9) is trading below our estimate of fair value (NOK119.2)

Significantly Below Fair Value: NAVA is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for NAVA?

Key metric: As NAVA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NAVA. This is calculated by dividing NAVA's market cap by their current earnings.
What is NAVA's PE Ratio?
PE Ratio23.3x
EarningsNOK 19.62m
Market CapNOK 457.47m

Price to Earnings Ratio vs Peers

How does NAVA's PE Ratio compare to its peers?

The above table shows the PE ratio for NAVA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average77.1x
VISTN Vistin Pharma
17.6xn/aNOK 1.1b
PHO Photocure
122.5x94.9%NOK 1.7b
AZT ArcticZymes Technologies
148.5x73.8%NOK 687.4m
539730 Fredun Pharmaceuticals
19.9xn/a₹3.5b
NAVA Navamedic
23.3x29.6%NOK 457.5m

Price-To-Earnings vs Peers: NAVA is good value based on its Price-To-Earnings Ratio (23.3x) compared to the peer average (77.1x).


Price to Earnings Ratio vs Industry

How does NAVA's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
NAVA 23.3xIndustry Avg. 19.3xNo. of Companies11PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: NAVA is expensive based on its Price-To-Earnings Ratio (23.3x) compared to the European Pharmaceuticals industry average (19.3x).


Price to Earnings Ratio vs Fair Ratio

What is NAVA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NAVA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio23.3x
Fair PE Ratio12.4x

Price-To-Earnings vs Fair Ratio: NAVA is expensive based on its Price-To-Earnings Ratio (23.3x) compared to the estimated Fair Price-To-Earnings Ratio (12.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NAVA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentNOK 25.90
NOK 37.00
+42.9%
2.7%NOK 38.00NOK 36.00n/a2
Dec ’25NOK 25.60
NOK 37.00
+44.5%
2.7%NOK 38.00NOK 36.00n/a2
Nov ’25NOK 25.00
NOK 45.50
+82.0%
1.1%NOK 46.00NOK 45.00n/a2
Oct ’25NOK 30.10
NOK 45.50
+51.2%
1.1%NOK 46.00NOK 45.00n/a2
Sep ’25NOK 29.10
NOK 45.50
+56.4%
1.1%NOK 46.00NOK 45.00n/a2
Aug ’25NOK 32.00
NOK 46.50
+45.3%
1.1%NOK 47.00NOK 46.00n/a2
Jul ’25NOK 33.00
NOK 46.50
+40.9%
1.1%NOK 47.00NOK 46.00n/a2
Jun ’25NOK 33.90
NOK 49.00
+44.5%
6.1%NOK 52.00NOK 46.00n/a2
May ’25NOK 32.40
NOK 49.00
+51.2%
6.1%NOK 52.00NOK 46.00n/a2
Apr ’25NOK 35.60
NOK 51.00
+43.3%
2.0%NOK 52.00NOK 50.00n/a2
Mar ’25NOK 37.00
NOK 49.00
+32.4%
2.0%NOK 50.00NOK 48.00n/a2
Feb ’25NOK 38.50
NOK 49.00
+27.3%
2.0%NOK 50.00NOK 48.00n/a2
Jan ’25NOK 36.70
NOK 49.00
+33.5%
2.0%NOK 50.00NOK 48.00n/a2
Dec ’24NOK 38.50
NOK 49.00
+27.3%
2.0%NOK 50.00NOK 48.00NOK 25.602
Nov ’24NOK 38.90
NOK 47.00
+20.8%
6.4%NOK 50.00NOK 44.00NOK 25.002
Oct ’24NOK 39.30
NOK 47.00
+19.6%
6.4%NOK 50.00NOK 44.00NOK 30.102
Sep ’24NOK 32.00
NOK 47.00
+46.9%
6.4%NOK 50.00NOK 44.00NOK 29.102
Aug ’24NOK 36.80
NOK 50.50
+37.2%
5.0%NOK 53.00NOK 48.00NOK 32.002
Jul ’24NOK 38.50
NOK 49.00
+27.3%
8.2%NOK 53.00NOK 45.00NOK 33.002
Jun ’24NOK 37.90
NOK 49.00
+29.3%
8.2%NOK 53.00NOK 45.00NOK 33.902
May ’24NOK 36.40
NOK 50.00
+37.4%
10.0%NOK 55.00NOK 45.00NOK 32.402
Apr ’24NOK 40.10
NOK 50.00
+24.7%
10.0%NOK 55.00NOK 45.00NOK 35.602
Mar ’24NOK 36.50
NOK 50.00
+37.0%
10.0%NOK 55.00NOK 45.00NOK 37.002

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 06:03
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Navamedic ASA is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Espen JørgensenDNB Markets
Gediminas RuginisNorne Securities AS
Juste SubataviciuteNorne Securities AS